FLT3 and acute myeloid leukemia: Gilteritinib monotherapy led to longer OS, higher rate of complete remission, and fewer serious adverse events than salvage chemotherapy and was approved for relapsed or refractory FLT3‐mutated AML who have a very poor prognosis.49, 50